SCHEMBL3774019

SCHEMBL3774019

COc1cnc(N2CCN(CC(=O)N3CCN(C4CCCC4)CC3)CC2)nc1

nearest known ligand 0.50

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 5/20 0.50
KMT2A Q03164 2/20 0.50
TSHR P16473 1/20 0.50
KDM4E B2RXH2 5/20 0.47
TDP1 Q9NUW8 2/20 0.47
HRH3 Q9Y5N1 2/20 0.47
ACHE P22303 1/20 0.44
PKM P14618 1/20 0.44
GRM5 P41594 1/20 0.43
ORAI1 Q96D31 1/20 0.42
RAB9A P51151 1/20 0.42
AURKA O14965 1/20 0.41
TP53 P04637 1/20 0.41
MEN1 O00255 1/20 0.41
POLB P06746 1/20 0.41
LMNA P02545 1/20 0.41
GAA P10253 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3767635 0.98 HRH3 (0.49) ALDH1A1KMT2ATSHRKDM4ETDP1
SCHEMBL3765950 0.88 ALDH1A1 (0.50) ALDH1A1KMT2ATSHRKDM4ETDP1
SCHEMBL3773951 0.86 ALDH1A1 (0.51) ALDH1A1KMT2ATSHRKDM4ETDP1
SCHEMBL3779247 0.85 ALDH1A1 (0.50) ALDH1A1KMT2AKDM4ETDP1HRH3
SCHEMBL3780719 0.84 ALDH1A1 (0.51) ALDH1A1KMT2ATSHRKDM4ETDP1
SCHEMBL13004952 0.84 KDM4E (0.67) ALDH1A1TSHRKDM4ETDP1TP53
SCHEMBL3776088 0.83 ALDH1A1 (0.48) ALDH1A1KMT2AKDM4ETDP1HRH3
SCHEMBL3762993 0.82 ALDH1A1 (0.60) ALDH1A1KMT2ATSHRKDM4ETDP1
SCHEMBL3774818 0.81 ALDH1A1 (0.62) ALDH1A1KMT2ATSHRKDM4ETDP1
SCHEMBL3763175 0.80 GAA (0.60) ALDH1A1KMT2ATSHRKDM4ETDP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7851474-B2 Dipiperazinyl ketones and related analogues NEUROGEN CORPORATION (US) 2010-12-14 US disclosed
US-7851474-B2 Dipiperazinyl ketones and related analogues NEUROGEN CORPORATION (US) 2010-12-14 US disclosed
US-7851474-B2 Dipiperazinyl ketones and related analogues NEUROGEN CORPORATION (US) 2010-12-14 US disclosed
US-20070049571-A1 Dipiperazinyl ketones and related analogues NEUROGEN CORPORATION 2007-03-01 US disclosed
US-20070049571-A1 Dipiperazinyl ketones and related analogues NEUROGEN CORPORATION 2007-03-01 US disclosed
US-20070049571-A1 Dipiperazinyl ketones and related analogues NEUROGEN CORPORATION 2007-03-01 US disclosed
WO-2007016496-A2 DIPIPERAZINYL KETONES AND RELATED ANALOGUES NEUROGEN CORPORATION (US) 2007-02-08 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070049571-A1 Dipiperazinyl ketones and related analogues HRH4, HRH3, HRH1 ALDH1A1 1210/4885KMT2A 242/4885TSHR 436/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.